| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-4895-5MG | AX-024 | 5mg | $189.00 | |
| GBM-4895-25MG | AX-024 | 25mg | $693.00 |
| Bioassays Specification | |
| Bio-Activity | Inhibits TCR-dependent T cell activation |
| Chemical Name | 1-[[4-(4-Fluorophenyl)-6-methoxy-2H-chromen-3-yl]methyl]pyrrolidine hydrochloride |
| Function / Pharmacology | Potent (IC50 ~ 1 nM) and specific inhibitor of T cell antigen receptor (TCR)-dependent T cell activation. Does not inhibit B cell proliferation triggered by B cell antigen receptor (BCR), TLR4, CD40 agonists nor IL-2-dependent proliferation of T lymphoblasts. Binds to the SH3.1 domain of the adaptor protein Nck blocking its interaction with the CD3ε subunit on the T cell antigen receptor. AX-024 displays protective effects in mouse models of psoriasis, allergic asthma, and multiple sclerosis. In contrast to fingolimod, the therapeutic effect of AX-024 persisted after removal of the drug, suggesting a persistent modification of autoimmune T cells. Currently in clinical trials. |
| CAS# | 1704801-24-0 |
| MW | 375.86 |
| Molecular Formula | C21H22FNO2 • HCl |
| Solubility | Soluble in DMSO (up to at least 25 mg/ml with warming) or in Water (up to 10 mg/ml with warming) |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Borroto et al. (2016), First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases; Sci. Transl. Med., 8 370ra184 |
| Protein Specification | |
| Purity | >98% |
| Bioassays Specification | |
| Bio-Activity | Inhibits TCR-dependent T cell activation |
| Chemical Name | 1-[[4-(4-Fluorophenyl)-6-methoxy-2H-chromen-3-yl]methyl]pyrrolidine hydrochloride |
| Function / Pharmacology | Potent (IC50 ~ 1 nM) and specific inhibitor of T cell antigen receptor (TCR)-dependent T cell activation. Does not inhibit B cell proliferation triggered by B cell antigen receptor (BCR), TLR4, CD40 agonists nor IL-2-dependent proliferation of T lymphoblasts. Binds to the SH3.1 domain of the adaptor protein Nck blocking its interaction with the CD3ε subunit on the T cell antigen receptor. AX-024 displays protective effects in mouse models of psoriasis, allergic asthma, and multiple sclerosis. In contrast to fingolimod, the therapeutic effect of AX-024 persisted after removal of the drug, suggesting a persistent modification of autoimmune T cells. Currently in clinical trials. |
| CAS# | 1704801-24-0 |
| MW | 375.86 |
| Molecular Formula | C21H22FNO2 • HCl |
| Solubility | Soluble in DMSO (up to at least 25 mg/ml with warming) or in Water (up to 10 mg/ml with warming) |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Borroto et al. (2016), First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases; Sci. Transl. Med., 8 370ra184 |
| Protein Specification | |
| Purity | >98% |
